ArticleInvestigational new drugs2021

Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling.

Minan Lu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.